Tolerx, Inc. Alternatives & Competitors

12 companies similar to Tolerx, Inc.

Novelogics Biotechnology Inc.

Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer us...

1 Angel

Canada

Biotechnology Health Care +1

ImmunoCellular Therapeutics Ltd

Pioneering immune-based therapies to harness the body's defenses against cancer through ad...

11 Grant $32.47M

Calabasas, United States

Biotechnology Health Care

VBL Therapeutics (Nasdaq:VBLT)

Engineering the future of targeted medicines, breaking barriers to develop the next genera...

15 Post-IPO Equity $62.76M

Israel

Biotechnology Health Care +1

Q32 Bio Inc.

Revolutionizing the future of targeted immune therapeutics

28 $255.50M

Waltham, United States

Biotechnology Health Care +1

Track all Tolerx, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Coley Pharmaceutical Group

Empowering the immune system to conquer illnesses and boost vaccine efficacy.

Post-IPO Equity $85.10M

Biotechnology Health Care

Prescient Therapeutics

A clinical stage oncology company developing personalised medicine approaches to cancer; c...

14 Post-IPO Equity $3.00M

Australia

Biopharma Biotechnology +3

Algiax Pharmaceuticals

Disarming chronic neuropathic pain

5 $4.30M

Erkrath, Germany

Biotechnology Health Care +1

Revitope

Powered for Precision: Revolutionizing immunotherapy to safely and effectively treat more...

6 Venture round $8.50M

Cambridge, United States

Biotechnology Health Care +1

Memgen, Inc.

Memgen's Vision: Develop Life-Saving Cancer Immunotherapies

7 Venture round

Houston, United States

Biotechnology Health Care +2

Abintus Bio, Inc.

Empowering patients from within

11 Venture round $13.65M

San Diego, United States

Biotechnology Health Care

RemAb Therapeutics

Removing harmful antibodies.

8 Grant $71.43K

Spain

Biotechnology Health Care

Elicio Therapeutics

Lymph-Node Targeted Immunotherapies

47 IPO $206.86M

Boston, United States

Biotechnology Health Care +2

About Tolerx, Inc.

Tolerx, Inc. is a trailblazer in immunology, with a remarkable array of pioneering drug candidates designed to combat not only type 1 diabetes, but also a range of autoimmune disorders and cancer by restoring balance to immune responses. The company's lineup features otelixizumab, its primary candidate in Phase 3 devel...

Taxonomy

Cancer Treatment, Diabetes Treatment, Autoimmune Disease, Immunotherapy, T Cell Immunotherapy, Drug Development, Clinical Trials, Immune Response Modulation, Antibody Treatment, Pharmaceuticals, Preclinical Candidates, Immune System Regulation, Viral Infections, Immune System Disorders

Frequently Asked Questions

Companies similar to Tolerx, Inc. include Novelogics Biotechnology Inc., ImmunoCellular Therapeutics Ltd, VBL Therapeutics (Nasdaq:VBLT), Q32 Bio Inc., Coley Pharmaceutical Group. They work in Biotechnology and Health Care and share Tolerx, Inc.'s focus on immunotherapy, drug development and cancer treatment.

Bounce Watch lists 12 companies that share Tolerx, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Tolerx, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Tolerx, Inc. Profile Novelogics Biotechnology Inc. Alternatives Q32 Bio Inc. Alternatives Abintus Bio, Inc. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Tolerx, Inc. on 12 Sep 2024. The 12 companies listed here were last checked between 21 Jun 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.